ESC 365 - Soluble guanylate cyclase activator vericiguat prevents anthracycline-mediated cardiotoxicity and sarcopenia through NO-sGC-cGMP-NLRP3 pathway

HFA Premium Access

Soluble guanylate cyclase activator vericiguat prevents anthracycline-mediated cardiotoxicity and sarcopenia through NO-sGC-cGMP-NLRP3 pathway

Session: How to improve prognosis in cardio-oncology

Topic: Cardio-Oncology

Speaker: Doctor N. Maurea (Naples, IT)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

2 presentations

2 followers

4 more presentations in this session

Cardiotoxicity in multiple myeloma patients in Hong Kong: a single-centre experience in the past decade

Speaker: Doctor M. Ho (Hong Kong, HK)

The predictive value of routine troponin measurements in patients treated with immune checkpoint inhibitors

Speaker: Doctor M. Laufer-Perl (Tel Aviv, IL)

Inherited cardiovascular disease mindset at cardio-oncology screening

Speaker: Doctor R. Lorca (Oviedo, ES)

Fluoropyrimidine chemotherapy and the risk of death and cardiovascular events in patients with gastrointestinal cancer: a cohort study

Speaker: Doctor A. Abiodun (London, GB)

Access the full session

How to improve prognosis in cardio-oncology

Speakers: Doctor N. Maurea, Doctor M. Ho, Doctor M. Laufer-Perl, Doctor R. Lorca, Doctor A. Abiodun

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources